Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. (December 2018)

• Record Type: Journal Article
• Authors: Wang, Yinghong; Wiesnoski, Diana; Helmink, Beth; Gopalakrishnan, Vancheswaran; Choi, Kati; DuPont, Hebert; Jiang, Zhi-Dong; Abu-Sbeih, Hamzah; Sanchez, Christopher; Chang, Chia-Chi; Parra, Edwin; Francisco-Cruz, Alejandro; Raju, Gottumukkala; Stroehlein, John; Campbell, Matthew; Gao, Jianjun; Subudhi, Sumit; Maru, Dipen; Blando, Jorge; Lazar, Alexander; Allison, James; Sharma, Padmanee; Tetzlaff, Michael; Wargo, Jennifer; Jenq, Robert
• Is Part Of: Nature medicine. Volume 24:Number 12(2018)
• Page Start: 1804
• Page End: 1808
• Publication Date: 2018-12
• Subjects: Pathology, Molecular -- Periodicals; Molecular biology -- Periodicals; 610.724
• DOI: 10.1038/s41591-018-0238-9
• Languages: English
• ISSNs: 1078-8956

Abstract

Abstract We report the first case series of immune checkpoint inhibitors (ICI)-associated colitis successfully treated with fecal microbiota transplantation, with reconstitution of the gut microbiome and a relative increase in the proportion of regulatory T-cells within the colonic mucosa. These preliminary data provide evidence that modulation of the gut microbiome may abrogate ICI-associated colitis. Preliminary evidence from two cases suggests that fecal microbiota transplantation may provide a viable treatment option for a severe adverse effect of immune checkpoint blockade therapy in patients with cancer.